Recently, it was reported that fenofibrate decreased the levels of many pro-inflammatory cytokines by inhibiting nuclear NF-κB p50 and p65 protein expression on the NF-κB signaling pathway, which likely contributed to its anti-inflammatory effects in PBC (107). Here, NFKB1 is linked to primary biliary cholangitis.